HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 315 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,358,122 | +234.6% | 166,443 | +215.9% | 0.02% | +240.0% |
| Q2 2023 | $1,900,276 | +15.0% | 52,683 | +21.8% | 0.01% | +25.0% |
| Q1 2023 | $1,652,366 | -55.4% | 43,267 | -33.6% | 0.00% | -60.0% |
| Q4 2022 | $3,708,515 | +27.0% | 65,176 | -11.7% | 0.01% | +11.1% |
| Q3 2022 | $2,920,000 | -20.6% | 73,841 | -11.6% | 0.01% | -10.0% |
| Q2 2022 | $3,676,000 | +7.0% | 83,547 | -3.0% | 0.01% | +25.0% |
| Q1 2022 | $3,436,000 | -58.9% | 86,161 | -58.6% | 0.01% | -50.0% |
| Q4 2021 | $8,364,000 | -36.1% | 208,023 | -35.3% | 0.02% | -36.0% |
| Q3 2021 | $13,088,000 | +23.6% | 321,716 | +37.9% | 0.02% | +25.0% |
| Q2 2021 | $10,593,000 | -34.2% | 233,278 | -39.6% | 0.02% | -35.5% |
| Q1 2021 | $16,090,000 | +53.2% | 385,937 | +57.0% | 0.03% | +47.6% |
| Q4 2020 | $10,501,000 | -6.2% | 245,873 | -42.3% | 0.02% | -19.2% |
| Q3 2020 | $11,193,000 | -2.7% | 425,920 | -0.8% | 0.03% | -7.1% |
| Q2 2020 | $11,508,000 | +971.5% | 429,266 | +619.4% | 0.03% | +833.3% |
| Q1 2020 | $1,074,000 | -80.8% | 59,667 | -81.1% | 0.00% | -75.0% |
| Q4 2019 | $5,588,000 | -32.3% | 315,207 | -40.8% | 0.01% | -40.0% |
| Q3 2019 | $8,260,000 | -41.5% | 532,517 | -35.2% | 0.02% | -41.2% |
| Q2 2019 | $14,118,000 | +5.4% | 821,783 | -1.3% | 0.03% | +3.0% |
| Q1 2019 | $13,399,000 | +47.0% | 832,243 | +33.5% | 0.03% | +32.0% |
| Q4 2018 | $9,118,000 | +197.3% | 623,210 | +269.1% | 0.02% | +257.1% |
| Q3 2018 | $3,067,000 | +71.8% | 168,827 | +59.6% | 0.01% | +40.0% |
| Q2 2018 | $1,785,000 | -48.9% | 105,812 | -40.6% | 0.01% | -50.0% |
| Q1 2018 | $3,490,000 | +90.5% | 178,130 | +97.0% | 0.01% | +100.0% |
| Q4 2017 | $1,832,000 | +92.2% | 90,421 | +64.8% | 0.01% | +66.7% |
| Q3 2017 | $953,000 | +13.5% | 54,863 | -16.3% | 0.00% | +50.0% |
| Q2 2017 | $840,000 | +35.5% | 65,513 | +37.0% | 0.00% | 0.0% |
| Q1 2017 | $620,000 | +30900.0% | 47,828 | +31365.8% | 0.00% | – |
| Q4 2016 | $2,000 | -91.7% | 152 | -92.4% | 0.00% | – |
| Q3 2016 | $24,000 | +20.0% | 2,004 | -12.6% | 0.00% | – |
| Q2 2016 | $20,000 | -9.1% | 2,294 | 0.0% | 0.00% | – |
| Q1 2016 | $22,000 | -70.7% | 2,294 | -47.0% | 0.00% | – |
| Q4 2015 | $75,000 | +3650.0% | 4,331 | +3206.1% | 0.00% | – |
| Q3 2015 | $2,000 | -87.5% | 131 | -81.8% | 0.00% | – |
| Q2 2015 | $16,000 | – | 718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |